RU2630694C2 - Азотсодержащее спироциклическое соединение и его применение в медицине - Google Patents
Азотсодержащее спироциклическое соединение и его применение в медицине Download PDFInfo
- Publication number
- RU2630694C2 RU2630694C2 RU2012106344A RU2012106344A RU2630694C2 RU 2630694 C2 RU2630694 C2 RU 2630694C2 RU 2012106344 A RU2012106344 A RU 2012106344A RU 2012106344 A RU2012106344 A RU 2012106344A RU 2630694 C2 RU2630694 C2 RU 2630694C2
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- mixture
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009179502 | 2009-07-31 | ||
| JP2009-179502 | 2009-07-31 | ||
| US27413709P | 2009-08-13 | 2009-08-13 | |
| US61/274137 | 2009-08-13 | ||
| PCT/JP2010/062873 WO2011013785A1 (ja) | 2009-07-31 | 2010-07-30 | 含窒素スピロ環化合物及びその医薬用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012106344A RU2012106344A (ru) | 2013-08-27 |
| RU2630694C2 true RU2630694C2 (ru) | 2017-09-12 |
Family
ID=43529436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012106344A RU2630694C2 (ru) | 2009-07-31 | 2010-07-30 | Азотсодержащее спироциклическое соединение и его применение в медицине |
Country Status (35)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2847397C2 (ru) * | 2019-05-15 | 2025-10-03 | Лео Фарма А/С | Лечение кожной формы красной волчанки |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| WO2011029043A1 (en) * | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
| BR112013003864B1 (pt) * | 2010-08-20 | 2021-08-31 | Hutchison Medipharma Limited | Compostos de pirrolpirimidina, composição e uso dos mesmos |
| PL2651417T3 (pl) | 2010-12-16 | 2017-08-31 | Calchan Limited | Pochodne pirolopirymidyny hamujące ASK1 |
| JP6075736B2 (ja) | 2011-12-21 | 2017-02-08 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | ピロール−６員ヘテロアリール環誘導体、その合成法およびその医薬用途 |
| US20140343034A1 (en) * | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| WO2015060208A1 (ja) | 2013-10-21 | 2015-04-30 | 日本たばこ産業株式会社 | 眼疾患の治療剤又は予防剤 |
| KR102518994B1 (ko) * | 2014-05-28 | 2023-04-05 | 아스트라제네카 아베 | Azd5363의 제조 방법 및 그에 사용되는 신규 중간체 |
| BR112017026173A2 (pt) * | 2015-07-07 | 2018-08-14 | Japan Tobacco, Inc. | Método para produção de derivado de 7h-pirrolo [2,3-d]pirimidina e intermediário do mesmo |
| WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
| CN108135834B (zh) | 2015-09-24 | 2021-07-27 | 利奥制药有限公司 | 斑秃的治疗 |
| KR102774784B1 (ko) * | 2015-09-25 | 2025-02-27 | 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 | Jak를 억제하기 위한 화합물 및 방법 |
| ES2963784T3 (es) * | 2016-01-21 | 2024-04-02 | Leo Pharma As | Uso de delgocitinib para el tratamiento del eccema crónico de manos |
| PE20190501A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores nmda espiro-lactam y metodos de uso de los mismos |
| WO2018095320A1 (zh) | 2016-11-23 | 2018-05-31 | 江苏恒瑞医药股份有限公司 | 吡咯并六元杂芳环类衍生物的制备方法及中间体 |
| BR112019012267A2 (pt) * | 2016-12-21 | 2019-12-03 | Japan Tobacco, Inc. | processo para a preparação do derivado de 7h-pirrolo [2,3-d]pirimidina e cocristais do mesmo |
| PL3560932T3 (pl) * | 2016-12-21 | 2026-06-29 | Japan Tobacco Inc. | Sposób wytwarzania pochodnych 7H‑pirolo[2,3‑d]pirymidyny i ich syntetycznych produktów pośrednich |
| TWI822666B (zh) * | 2016-12-21 | 2023-11-21 | 日商日本煙草產業股份有限公司 | Ｊａｎｕｓ激酶抑制劑之結晶型 |
| CN110291090A (zh) * | 2017-01-20 | 2019-09-27 | 利奥制药有限公司 | 作为新型jak激酶抑制剂的双环胺 |
| US10799507B2 (en) * | 2017-02-03 | 2020-10-13 | Leo Pharma A/S | 5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2.5]octane-8-carboxylic acid derivatives as novel JAK kinase inhibitors |
| MX2020003821A (es) * | 2017-10-10 | 2023-01-12 | Biogen Inc | Proceso de elaboración de espiroderivados. |
| JP2021512109A (ja) * | 2018-01-31 | 2021-05-13 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用 |
| WO2020007698A1 (en) * | 2018-07-06 | 2020-01-09 | Leo Pharma A/S | Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| FI3968997T3 (fi) | 2019-05-15 | 2026-06-09 | Leo Pharma As | Delgositinibin formulaatio voiteen muodossa |
| JP7597714B2 (ja) * | 2019-08-07 | 2024-12-10 | ロート製薬株式会社 | 涙液分泌促進用眼科組成物 |
| CN119367282A (zh) * | 2019-12-27 | 2025-01-28 | 乐敦制药株式会社 | 水性组合物 |
| CN111606929B (zh) * | 2020-06-30 | 2023-07-07 | 中瀚(齐河县)生物医药科技有限公司 | 德高替尼的制备方法 |
| CN111560021B (zh) * | 2020-06-30 | 2023-05-26 | 上海鲲博玖瑞医药科技发展有限公司 | 一种德高替尼中间体及其制备方法 |
| CN111574540B (zh) * | 2020-06-30 | 2023-08-29 | 云南华派医药科技有限公司 | 一种德高替尼的制备方法 |
| TW202227452A (zh) * | 2020-12-04 | 2022-07-16 | 大陸商廣州費米子科技有限責任公司 | 氮雜並環化合物、其製備方法、抑制酪氨酸激酶的方法、藥物組成物及其用途 |
| TW202241439A (zh) * | 2020-12-29 | 2022-11-01 | 大陸商上海岸闊醫藥科技有限公司 | 治療與抗腫瘤劑相關的皮膚疾病或病症的試劑和方法 |
| JP2025514747A (ja) | 2022-04-20 | 2025-05-09 | レオ ファーマ アクティーゼルスカブ | 前頭部線維性脱毛症の治療 |
| AU2024229918A1 (en) | 2023-02-28 | 2025-09-18 | Assia Chemical Industries Ltd. | Solid state forms of delgocitinib and process thereof |
| JP2026509302A (ja) | 2023-03-17 | 2026-03-17 | レオ ファーマ アクティーゼルスカブ | 中等症ないし重症の慢性手湿疹を有する患者における慢性手湿疹を処置する方法 |
| WO2024225445A1 (en) | 2023-04-27 | 2024-10-31 | Japan Tobacco Inc. | Crystalline form of delgocitinib |
| WO2025085050A1 (en) * | 2023-10-16 | 2025-04-24 | Leo Pharma A/S | Treatment of frontal fibrosing alopecia |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002518393A (ja) * | 1998-06-19 | 2002-06-25 | ファイザー・プロダクツ・インク | ピロロ［２．３−ｄ］ピリミジン化合物 |
| JP2002518394A (ja) * | 1998-06-19 | 2002-06-25 | ファイザー・プロダクツ・インク | ピロロ［２，３−ｄ］ピリミジン化合物 |
| WO2006069080A2 (en) * | 2004-12-22 | 2006-06-29 | Incyte Corporation | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors |
| WO2007007919A2 (en) * | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
| WO2008119792A1 (en) * | 2007-04-02 | 2008-10-09 | Palau Pharma, S. A. | Pyrrolopyrimidine derivatives as jak3 inhibitors |
| JP2008545660A (ja) * | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピロロピリジン化合物 |
| JP2009520725A (ja) * | 2005-12-22 | 2009-05-28 | ノバルティス アクチエンゲゼルシャフト | ヤヌスキナーゼ阻害剤であるスルホンアミドアニリン誘導体 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0103836A3 (en) | 1998-06-02 | 2003-05-28 | Osi Pharmaceuticals Inc Uniond | Pyrrolo[2,3d]pyrimidine compositions and their use |
| OA12118A (en) * | 1999-12-10 | 2006-05-04 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds. |
| PT1519939E (pt) * | 2002-07-05 | 2010-02-10 | Targacept Inc | Compostos n-arildiazaspirocíclicos e métodos para a sua preparação e utilização |
| WO2005047286A1 (ja) | 2003-11-13 | 2005-05-26 | Ono Pharmaceutical Co., Ltd. | スピロ複素環化合物 |
| US20090111805A1 (en) | 2005-02-24 | 2009-04-30 | Pfizer Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| US20070208001A1 (en) | 2006-03-03 | 2007-09-06 | Jincong Zhuo | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| WO2008029237A2 (en) | 2006-09-05 | 2008-03-13 | Pfizer Products Inc. | Combination therapies for rheumatoid arthritis |
| CA2674518A1 (en) | 2006-12-22 | 2008-07-03 | F.Hoffmann-La Roche Ag | Spiro-piperidine derivatives |
| CL2008000467A1 (es) * | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma |
| WO2009047255A1 (en) * | 2007-10-09 | 2009-04-16 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| TW200940542A (en) | 2008-01-09 | 2009-10-01 | Array Biopharma Inc | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| CA2728559A1 (en) | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
| NZ596479A (en) | 2009-05-22 | 2014-01-31 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| WO2011029043A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
| JP2018028525A (ja) * | 2016-08-15 | 2018-02-22 | 小野 信行 | イオンレーザーと重水素を利用した核融合炉 |
| JP6229778B2 (ja) * | 2016-09-21 | 2017-11-15 | サミー株式会社 | 遊技機 |
-
2010
- 2010-07-22 TW TW99124110A patent/TWI466885B/zh active
- 2010-07-23 AR ARP100102681A patent/AR077497A1/es active IP Right Grant
- 2010-07-30 HU HUE10804531A patent/HUE033070T2/hu unknown
- 2010-07-30 SM SM20170166T patent/SMT201700166T1/it unknown
- 2010-07-30 AU AU2010278066A patent/AU2010278066B2/en active Active
- 2010-07-30 PT PT108045311T patent/PT2460806T/pt unknown
- 2010-07-30 SG SG2011094117A patent/SG176918A1/en unknown
- 2010-07-30 PE PE2012000097A patent/PE20121276A1/es active IP Right Grant
- 2010-07-30 RS RS20170305A patent/RS55913B1/sr unknown
- 2010-07-30 EP EP17150170.3A patent/EP3181570A1/en not_active Withdrawn
- 2010-07-30 SI SI201031426A patent/SI2460806T1/sl unknown
- 2010-07-30 PL PL10804531T patent/PL2460806T3/pl unknown
- 2010-07-30 US US12/847,025 patent/US8609647B2/en active Active
- 2010-07-30 MX MX2012001313A patent/MX2012001313A/es active IP Right Grant
- 2010-07-30 HR HRP20170447TT patent/HRP20170447T1/hr unknown
- 2010-07-30 NZ NZ597994A patent/NZ597994A/xx unknown
- 2010-07-30 WO PCT/JP2010/062873 patent/WO2011013785A1/ja not_active Ceased
- 2010-07-30 KR KR1020127001455A patent/KR101773208B1/ko active Active
- 2010-07-30 CA CA2767899A patent/CA2767899C/en active Active
- 2010-07-30 ME MEP-2017-74A patent/ME02667B/me unknown
- 2010-07-30 LT LTEP10804531.1T patent/LT2460806T/lt unknown
- 2010-07-30 CN CN201080034068.1A patent/CN102510865B/zh active Active
- 2010-07-30 BR BR112012002157-5A patent/BR112012002157B1/pt active IP Right Grant
- 2010-07-30 EP EP10804531.1A patent/EP2460806B1/en active Active
- 2010-07-30 EP EP21159390.0A patent/EP3858349A1/en not_active Withdrawn
- 2010-07-30 MY MYPI2012000155A patent/MY163495A/en unknown
- 2010-07-30 ES ES10804531.1T patent/ES2616705T3/es active Active
- 2010-07-30 JP JP2010171260A patent/JP5520158B2/ja active Active
- 2010-07-30 RU RU2012106344A patent/RU2630694C2/ru active
- 2010-07-30 DK DK10804531.1T patent/DK2460806T3/en active
-
2011
- 2011-12-18 IL IL217048A patent/IL217048A/en active IP Right Grant
-
2012
- 2012-01-18 CO CO12006869A patent/CO6491052A2/es active IP Right Grant
- 2012-01-27 ZA ZA2012/00689A patent/ZA201200689B/en unknown
-
2013
- 2013-11-12 US US14/077,446 patent/US20140187534A1/en not_active Abandoned
-
2014
- 2014-04-04 JP JP2014077850A patent/JP2014141516A/ja active Pending
-
2015
- 2015-11-17 JP JP2015224910A patent/JP2016029104A/ja not_active Ceased
-
2016
- 2016-11-02 JP JP2016214954A patent/JP2017019877A/ja not_active Ceased
-
2017
- 2017-03-20 CY CY20171100348T patent/CY1118747T1/el unknown
-
2018
- 2018-02-21 JP JP2018028525A patent/JP2018111701A/ja not_active Ceased
-
2019
- 2019-12-04 JP JP2019219283A patent/JP2020033384A/ja not_active Withdrawn
-
2021
- 2021-09-06 JP JP2021144545A patent/JP2021183653A/ja not_active Withdrawn
- 2021-12-21 US US17/557,174 patent/US20230023377A1/en not_active Abandoned
-
2023
- 2023-05-05 US US18/143,720 patent/US20240150367A1/en not_active Abandoned
- 2023-08-07 JP JP2023128376A patent/JP2023138641A/ja not_active Withdrawn
-
2025
- 2025-02-28 FI FIC20250012C patent/FIC20250012I1/fi unknown
- 2025-02-28 FR FR25C1010C patent/FR25C1010I2/fr active Active
- 2025-02-28 CY CY2025008C patent/CY2025008I2/el unknown
- 2025-03-03 LT LTPA2025511C patent/LTC2460806I2/lt unknown
- 2025-03-03 HU HUS2500013C patent/HUS2500013I1/hu unknown
- 2025-03-04 NL NL301321C patent/NL301321I2/nl unknown
- 2025-05-08 JP JP2025077764A patent/JP2025109780A/ja not_active Withdrawn
Patent Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002518393A (ja) * | 1998-06-19 | 2002-06-25 | ファイザー・プロダクツ・インク | ピロロ［２．３−ｄ］ピリミジン化合物 |
| JP2002518394A (ja) * | 1998-06-19 | 2002-06-25 | ファイザー・プロダクツ・インク | ピロロ［２，３−ｄ］ピリミジン化合物 |
| EA005852B1 (ru) * | 1998-06-19 | 2005-06-30 | Пфайзер Продактс Инк. | ПИРРОЛО[2,3-d]ПИРИМИДИНЫ |
| EA006034B1 (ru) * | 1998-06-19 | 2005-08-25 | Пфайзер Продактс Инк. | ПИРРОЛО[2,3-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ |
| EA010377B1 (ru) * | 1998-06-19 | 2008-08-29 | Пфайзер Продактс, Инк. | ПИРРОЛО[2,3-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ |
| JP2008525463A (ja) * | 2004-12-22 | 2008-07-17 | インサイト・コーポレイション | ＪＡＮＵＳキナーゼ阻害剤としてのピロロ［２，３−ｂ］ピリジン−４−イル−アミンおよびピロロ［２，３−ｂ］ピリミジン−４−イル−アミン |
| WO2006069080A2 (en) * | 2004-12-22 | 2006-06-29 | Incyte Corporation | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors |
| JP2008545660A (ja) * | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピロロピリジン化合物 |
| RU2011133825A (ru) * | 2005-05-20 | 2013-02-20 | Вертекс Фармасьютикалз Инкорпорейтед | Пирролопиридины, полезные в качестве ингибиторов протеинкиназы |
| WO2007007919A2 (en) * | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
| JP2009501130A (ja) * | 2005-07-14 | 2009-01-15 | アステラス製薬株式会社 | ヘテロ環ヤヌスキナーゼ３阻害剤 |
| JP2009520725A (ja) * | 2005-12-22 | 2009-05-28 | ノバルティス アクチエンゲゼルシャフト | ヤヌスキナーゼ阻害剤であるスルホンアミドアニリン誘導体 |
| RU2008129379A (ru) * | 2005-12-22 | 2010-01-27 | Новартис АГ (CH) | Производные сульфонамидоанилина, являющиеся ингибиторами киназы януса (janus) |
| WO2008119792A1 (en) * | 2007-04-02 | 2008-10-09 | Palau Pharma, S. A. | Pyrrolopyrimidine derivatives as jak3 inhibitors |
| RU2009140319A (ru) * | 2007-04-02 | 2011-05-10 | Палау Фарма С.А. (Es) | Производные пирролпиримидина |
Non-Patent Citations (1)
| Title |
|---|
| Jian-kang Jiang et al.,Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690, 550), Journal of Medicinal Chemistry, 2008, Vol: 51, Nr: 24, Page(s): 8012 - 8018. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2847397C2 (ru) * | 2019-05-15 | 2025-10-03 | Лео Фарма А/С | Лечение кожной формы красной волчанки |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240150367A1 (en) | Nitrogen-containing spiro cyclic compounds and pharmaceutical use thereof | |
| US10851116B2 (en) | Bicyclic amines as novel JAK kinase inhibitors | |
| WO2021170631A1 (en) | Difluorocyclohexyl derivatives as il-17 modulators | |
| EP3844159B1 (en) | Novel pyrrolidinyl amide compounds for the treatment of autoimmune disease | |
| US20230049231A1 (en) | ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | |
| HK1166499A (en) | Nitrogen-containing spiro-ring compound and medicinal use of same | |
| HK1166499B (en) | Nitrogen-containing spiro-ring compound and medicinal use of same | |
| EP4709486A1 (en) | Heteroaryl compounds as ligand directed degraders of irak4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner |